Last reviewed · How we verify
NCT03514238: iMET
The Irisin and Metabolic Exercise Training Study
NA trial testing High Intensity Interval Aerobic Exercise (HIIT) in Obesity in 40 participants. Completed in 1 November 2019.
1 November 2019
Quick facts
| Lead sponsor | University of New Brunswick |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | none |
| Primary purpose | prevention |
| Enrollment | 40 |
| Start date | 1 September 2017 |
| Primary completion | 1 November 2019 |
| Estimated completion | 1 November 2019 |
| Sites | 1 location across Canada |
Drugs / interventions tested
- High Intensity Interval Aerobic Exercise (HIIT)
- Continuous Moderate Aerobic Exercise (MOD)
- Control Sitting Condition (C)
Conditions studied
- Obesity — all drugs for Obesity →
Sponsor
University of New Brunswick
Who can join
Adults 19 to 50, any sex, with Obesity. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
It has been established that greater amounts of vigorous intensity physical activity lead to improved health outcomes. Interestingly, the response of biologically active substances, called myokines, differs according to exercise intensity. As such, the current study aims to compare the difference in the response to irisin according to different exercise intensities in both normal weight subjects and individuals living with obesity. This study will compare continuous moderate intensity physical activity to high intensity physical activity against a control condition. Furthermore, this study will determine whether differences in exercise intensity are associated with better insulin sensitivity.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
An examination of exercise intensity and its impact on the acute release of irisin across obesity status: a randomized controlled crossover trial.
Rioux B, Paudel Y, Thomson A, Peskett L, et al · · 2024 · cited 3× · PMID 39226615 · DOI 10.1139/apnm-2024-0091
Verify or expand the search:
- PubMed search for NCT03514238
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Obesity
Currently open trials in the same condition.
- NCT07403604 — Effect of Insulin Lowering on Lipogenesis · Phase 1 · recruiting
- NCT07509307 — AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee · Phase 3 · recruiting
- NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
- NCT07481630 — A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoart · Phase 3 · recruiting
- NCT07527195 — Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscl · Phase 1 · recruiting
Other University of New Brunswick trials
Trials by the same sponsor.
- NCT07309536 — Mediterranean Diet Uptake and Nutrition on Child Health, Inflammation, and Early-life Symbiosis (MUNCHIES) Study · NA · not yet recruiting
- NCT06285786 — Patient Handling Techniques and New Technology for Health Care Workers · NA · unknown
- NCT05385458 — Acceptance and Commitment Therapy (ACT) Tele-Counselling · NA · completed
- NCT05615831 — The Impact of Exercise With Blood Flow Restriction: Sex and Age Differences · NA · completed
- NCT04997681 — SYNchronizing Exercises, Remedies in Gait and Cognition at Home (SYNERGIC@Home) · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03514238 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of New Brunswick
- Last refreshed: 3 November 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03514238.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing